Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCHR1 | Q99705 | 5/20 | 0.41 |
| ▸ | HRH3 | Q9Y5N1 | 10/20 | 0.37 |
| ▸ | KCNH2 | Q12809 | 7/20 | 0.37 |
| ▸ | HTR1D | P28221 | 1/20 | 0.36 |
| ▸ | HTR1B | P28222 | 1/20 | 0.36 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.35 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.35 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.35 |
| ▸ | ACHE | P22303 | 1/20 | 0.33 |
| ▸ | HTR2C | P28335 | 1/20 | 0.33 |
| ▸ | HTR2B | P41595 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4130994 | 0.91 | HRH3 (0.41) | MCHR1HRH3KCNH2HTR1DHTR1B | |
| SCHEMBL4139723 | 0.90 | MCHR1 (0.37) | MCHR1HRH3KCNH2OPRM1HTR2C | |
| SCHEMBL4136104 | 0.89 | MCHR1 (0.36) | MCHR1HRH3KCNH2HTR1DHTR1B | |
| SCHEMBL4136315 | 0.88 | HRH3 (0.39) | MCHR1HRH3KCNH2HTR1DHTR1B | |
| SCHEMBL4127329 | 0.88 | HTR1A (0.42) | MCHR1HRH3KCNH2CYP11B1CYP11B2 | |
| SCHEMBL4135531 | 0.87 | S1PR1 (0.42) | MCHR1HRH3KCNH2 | |
| SCHEMBL4141039 | 0.87 | HRH3 (0.45) | MCHR1HRH3KCNH2HTR1DHTR1B | |
| SCHEMBL4128192 | 0.86 | HRH3 (0.39) | MCHR1HRH3KCNH2CYP11B1CYP11B2 | |
| SCHEMBL4140976 | 0.84 | MCHR1 (0.36) | MCHR1HRH3KCNH2 | |
| SCHEMBL4132406 | 0.84 | MCHR1 (0.37) | MCHR1HRH3KCNH2HTR1DHTR1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090163482-A1 | TETRALINES ANTAGONISTS OF THE H-3 RECEPTOR | MCHARDY STANTON FURST | 2009-06-25 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090163482-A1 | TETRALINES ANTAGONISTS OF THE H-3 RECEPTOR | HRH3, HRH4, HRH1 | MCHR1 287/4885HRH3 1/4885KCNH2 657/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.